Ambrx Revenue and Competitors

Location

#4979

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Ambrx's estimated annual revenue is currently $12.3M per year.(i)
  • Ambrx's estimated revenue per employee is $110,991
  • Ambrx's total funding is $347.9M.
  • Ambrx's current valuation is $213.2M. (January 2022)

Employee Data

  • Ambrx has 111 Employees.(i)
  • Ambrx grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. By combing the versatility of medicinal chemistry with modern biotechnology, Ambrx is transforming the field of protein-based medicines. Ambrx completed a $12.5 million Series A preferred stock financing from investors including 5AM Ventures and Tavistock Life Sciences. Ambrx is based in San Diego, California and is currently recruiting a world-class scientific and commercialization team.

keywords:Biotechnology

$347.9M

Total Funding

111

Number of Employees

$12.3M

Revenue (est)

11%

Employee Growth %

$213.2M

Valuation

N/A

Accelerator

Ambrx News

2022-03-22 - Ambrx Biopharma Inc. to Participate in the Cowen 42nd ...

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code ... for drug candidates generated using Ambrx technology.

2021-01-07 - Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive leadership experience in raising capital, building biotech companies, and leading organizations to deve ...

2020-11-23 - $200M investment to advance clinical programs for Ambrx

Investors in the $200 million round include Fidelity Management & Research Co., Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management, as well as funds and accounts managed by BlackRock. Ambrx also has struck partnerships with larg ...

2020-11-10 - Ambrx Raises $200M More

San Diego-based biopharmaceuticals developer Ambrx has raised $200M in a funding round, according to the company, which included Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partn ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.3M1117%N/A
#2
$34.2M11156%N/A
#3
$27.9M11118%N/A
#4
$36.6M111-3%N/A
#5
$34.2M1119%N/A